News & Updates
Filter by Specialty:
IV, SC doses of biologic combo effective in asymptomatic, low-risk COVID-19 patients
07 Sep 2022
All intravenous (IV) and subcutaneous (SC) doses of the monoclonal antibody combination of casirivimab plus imdevimab effectively reduces viral load in COVID-19 patients with asymptomatic or low-risk symptomatic infection, according to the results of a phase II study.
IV, SC doses of biologic combo effective in asymptomatic, low-risk COVID-19 patients
07 Sep 2022Dietary cholesterol consumption may lead to subsequent type 2 diabetes
07 Sep 2022
There appears to be a positive dose-response association between dietary cholesterol and type 2 diabetes mellitus (T2DM), where the higher the intake, the greater the incidence of T2DM especially in Western countries, according to a study.